Research overview
The text below is the source article’s original abstract under a verified reuse license. cc by
Abstract The NLRP3 inflammasome is a central mediator of metabolic inflammation, yet the upstream mechanisms remain poorly defined. We identified RGS10 as a critical regulator of NLRP3-driven immunometabolic responses. In macrophages, loss of RGS10 enhanced calcium-dependent NLRP3 inflammasome activity during both priming and activation. In high-fat diet-fed male mice, Nlrp3 deletion improved glucose tolerance, adipose remodeling, and hepatic and hypothalamic pathology, whereas Rgs10 deletion induced the opposite phenotype. These benefits required RGS10: in Nlrp3 -/-/ Rgs10 -/- (dKO) males, the improvements in glucose tolerance, adipose remodeling, and hypothalamic microgliosis were abolished. This requirement was selective; RGS10 acted dominantly to restrain myeloid and hepatic inflammation independent of NLRP3, and the interaction was sex-dependent. Finally, RGS10 declined in aged and Parkinson’s disease human microglia, and aged Rgs10 -/- mice developed glucose intolerance. Together, these findings establish RGS10 as a dominant, sex-dependent upstream regulator of NLPR3-driven inflammation, suggesting that age- or inflammation-associated RGS10 loss may limit the efficacy of NLRP3-targeted therapies.
Scientific assessment
Research question
Assess the question within the original study’s scope.
Methods & sample
Check the source article for study design and sample details.
Key findings
An editorially approved findings summary is not yet published for this record.
Limitations
Generalizability, bias and clinical meaning require separate assessment.
Methods, samples and clinical conclusions are not inferred from bibliographic metadata.